United States: Purdue OxyContin Patents Invalid Despite Stemming From Discovery Of Source Of Toxic Impurity

In Purdue Pharma L.P. v. Epic Pharma LLC, the Federal Circuit affirmed the district court decision holding four OxyContin patents invalid as obvious. In so doing, the court rejected Purdue’s arguments that its discovery of the source of the toxic impurity that was minimized in the claimed products did not support patentability, because the solution to the problem did not depend on the source of the impurity.

The Perdue OxyContin Patents At Issue

There were four OxyContin® patents at issue, three of which claimed products having a low level of the toxic impurity referred to as “ABUKs” (α,β-unsaturated ketones) (U.S. Patent No. 7,674,799, U.S. Patent No. 7,674,800, and U.S. Patent No. 7,683,072), and one of which related to an abuse-resistant formulation (U.S. Patent No. 8,114,383). This article will focus on the court’s treatment of the “low-ABUK patents.”

According to the Federal Circuit decision, prior to the invention at issue oxycodone hydrochloride was made by a three-step process:

  • oxidizing thebaine to form 14-hydroxycodeinone (referred to in the decision as “14-hydroxy”)
  • converting 14-hydroxy to oxycodone free base by hydrogenation
  • reacting oxycodone free base with hydrochloric acid to form oxycodone hydrochloride

However, this process resulted in a final product with “high levels of 14- hydroxy, on the order of 1500 parts per million.” Since that compound was believed to be toxic, Purdue investigated how to make a product with lower levels of 14- hydroxy.

Its investigations led to the discovery that a particular isomer (8α, 14–dihydroxy–7,8– dihydrocodeinone ("8α")) was produced during the first step of the prior art process, and that the isomer was converted to 14-hydroxy during step three of the process. To solve this problem, Purdue added an additional hydrogenation step as a fourth step of the process, such that 14-hydroxy present after step three is converted to oxycodone free base in new step four.

Claim 1 of the ‘072 patent recites:

1. An oxycodone hydrochloride active pharmaceutical ingredient having less than 25 ppm 14-hydroxycodeinone, wherein at least a portion of the 14:hydroxycodeinone is derived from 8α,14-dihydroxy-7,8-dihydrocodeinone.

Claim 1 of the ‘799 patent recites:

1. An oral dosage form comprising particles, the particles comprising from about 5 mg to about 320 mg oxycodone hydrochloride active pharmaceutical ingredient having less than 25 ppm 14-hydroxycodeinone, wherein at least a portion of the 14-hydroxycodeinone is derived from 8α,14-dihydroxy-7,8-dihydrocodeinone during conversion of oxycodone free base to oxycodone hydrochloride, said particles being coated with an amount of hydrophobic material effective to provide a sustained release of the oxycodone hydrochloride when the coated particles are exposed to an aqueous solution.

Claim 30 of the ‘800 patent recites “Oxycodone salt prepared according to the process of claim 1,” where claim 1 recites:

1. A process for preparing an oxycodone salt substantially free of 14-hydroxycodeinone, which process comprises steps of: (a) preparing a mixture of oxycodone free base, solvent and an acid, the oxycodone free base having an 8α,14-dihydroxy-7,8-dihydrocodeinone component; (b) incubating the mixture under conditions suitable to convert the oxycodone free base to an oxycodone salt, wherein said conditions promote an acid catalyzed dehydration consisting of conversion of the 8α,14-dihydroxy-7,8-dihydrocodeinone component to 14-hydroxycodeinone; and (c) preferentially removing the 14-hydroxycodeinone from the oxycodone salt.

The District Court Decision

Purdue commenced the district court litigation in response to Abbreviated New Drug Applications (ANDAs) filed by Amneal Pharmaceuticals, LLC, Epic Pharma, LLC, Mylan Pharmaceuticals Inc., and Teva Pharmaceuticals USA, Inc. As summarized in the Federal Circuit decision, the district court found that all asserted claims were obvious on the grounds that “the prior art taught that oxidation of thebaine produced 14- hydroxy and that it was well known in the art that 14- hydroxy could be removed using hydrogenation.” The district court “determined that the discovery of 8α was not necessary to the claimed invention,” because “a skilled artisan would recognize that hydrogenation could be used to remove the remaining 14-hydroxy, regardless of the source of the 14-hydroxy.” The court also “concluded that the claim limitation requiring that the remaining 14-hydroxy is at least in part ‘derived from 8α[]’ is a product-by-process limitation and thus immaterial in the obviousness determination.”

The Federal Circuit Decision

The Federal Circuit decision was authored by Chief Judge Prost and joined by Judge Reyna and Chief District Judge Stark of the U.S. District Court for the District of Delaware, sitting by designation.

Chief Judge Prost noted that the parent application of the low-ABUK patents was before the court in 2009, when the court affirmed the USPTO Board’s rejection of the claims as obvious. Those claims were directed to the four-step manufacturing method, but “did not require that some of the remaining 14-hydroxy be derived from the 8α isomer.”

The Federal Circuit decision addresses three main Purdue arguments:

In response to Purdue’s argument that its “discovery of 8α as the core of the claimed inventions” should have been given more weight, the Federal Circuit distinguished the Supreme Court decision Purdue relied upon (Eibel Process Co. v. Minnesota & Ontario Paper Co., 261 U.S. 45 (1923)), because the “problem [of the source of the 14-hydroxy] did not need to be solved to arrive at the claimed invention.”

The issue again comes down to whether it would be obvious to a person having ordinary skill in the art to use hydrogenation to remove the excess 14-hydroxy in the oxycodone API. One need not know that the 14-hydroxy was derived from 8α as opposed to 8β to answer that question.

In response to Purdue’s argument that the requirement that “the remaining 14-hydroxy in the oxycodone API is derived from 8α” supports nonobviousness “because 8α was not previously known in the art as being the source of 14-hydroxy,” the Federal Circuit agreed with the district court that "because the clause at issue “does not describe the structure of 14-hydroxy” it “thus is a process limitation.” The Federal Circuit also noted that “the fact that the 14-hydroxy is derived from 8α imparts no structural or functional differences in the low-ABUK hydrocodone API as compared to the prior art products.”

In response to Purdue’s arguments of secondary considerations (the commercial success of Purdue’s API supplier, failure of others, praise by competitors), the Federal Circuit found no clear error in the district court’s findings of lack of nexus to the claimed invention or inadequate factual support.

The court therefore affirmed the district court decision holding the asserted claims of the low-ABUK patents to be invalid.

The Importance Of Product Claims

Purdue’s efforts to obtain a variety of product claims may reflect the importance of obtaining product claims to protect a pharmaceutical product. Patents that only claim a method of manufacturing a drug cannot be listed in the Orange Book, which means that would-be generic companies do not need to file Paragraph IV certifications against them with their ANDA applications. Method of manufacture claims also may be more susceptible to design-around options. For example, the Federal Circuit noted that Teva did not use the Purdue process to make its product. Still, method of manufacture claims can be valuable, particularly if they protect a commercially advantageous way to make the drug, or result in an improved product.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.